Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

NCT05092360 is registered in ClinicalTrials.gov with Mural Oncology, Inc as lead sponsor.

NCT NCT05092360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05092360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)
Lead sponsor
Mural Oncology, Inc
Phase
Phase 3
Overall status
Terminated
Start date
January 10, 2022
Completion date
May 8, 2025
Enrollment
456 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, platinum-resistant ovarian cancer, primary peritoneal cancer